WWP2 is an E3 ubiquitin ligase for PTEN

Nature Cell Biology

Volumn 13, Issue 6, 2011, Pages 728-733

  Maddika, Subbareddy ^a   Kavela, Sridhar ^a   Rani, Neelam ^a   Palicharla, Vivek Reddy ^a   Pokorny, Jenny L ^b   Sarkaria, Jann N ^b   Chen, Junjie ^c  

^a CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPHIN 1 INTERACTING PROTEIN 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL FATE; CELL SURVIVAL; CELL TRANSPORT; CONTROLLED STUDY; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PURIFICATION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; TUMOR CELL; UBIQUITINATION;

CELL LINE, TUMOR; HUMANS; MALE; NEOPLASMS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 79957926724     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2240     Document Type: Article

References (40)

1. Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W. & Leal, J. F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current Cancer Drug Targets 8, 187-198 (2008). (Pubitemid 351688437)
2. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997). (Pubitemid 27148818)
3. Steck, P.A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356-362 (1997). (Pubitemid 27147102)
4. Guldberg, P. et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 57, 3660-3663 (1997). (Pubitemid 27381203)
5. Rhei, E. et al. Mutation analysis of the putative tumour suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res. 57, 3657-3659 (1997). (Pubitemid 27381202)
6. Wang, S. I., Parsons, R. & Ittmann, M. Homozygous deletion of the PTEN tumour suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 4, 811-815 (1998). (Pubitemid 28193582)
7. Wang, S. I. et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183-4186 (1997). (Pubitemid 27413419)
8. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348-355 (1998). (Pubitemid 28357906)
9. Kwabi-Addo, B. et al. Haploinsufficiency of the Pten tumour suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98, 11563-11568 (2001). (Pubitemid 32928768)
10. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
11. Blumenthal, G. M. & Dennis, P. A. PTEN hamartoma tumour syndromes. Euro. J. Hum. Genet. 16, 1289-1300 (2008).
12. Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16, 64-67 (1997). (Pubitemid 27198157)
13. Marsh, D. J. et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 16, 333-334 (1997).
14. Myers, M.P. et al. The lipid phosphatase activity of PTEN is critical for its tumour supressor function. Proc. Natl. Acad. Sci. USA 95, 13513-13518 (1998). (Pubitemid 28523003)
15. Myers, M. P. et al. P-TEN, the tumour suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. USA 94, 9052-9057 (1997).
16. Osaki, M., Oshimura, M. & Ito, H. PI3K-AKT pathway: its functions and alterations in human cancer. Apoptosis 9, 667-676 (2004). (Pubitemid 40941196)
17. Paez, J. & Sellers, W. R. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signalling. Cancer Treatment Res. 115, 145-167 (2003).
18. Maddika, S. et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10, 13-29 (2007). (Pubitemid 46636381)
19. Stambolic, V. et al. Negative regulation of PKB/AKT-dependent cell survival by the tumour suppressor PTEN. Cell 95, 29-39 (1998). (Pubitemid 28458022)
20. Reddy, P. et al. Oocyte-specific deletion of Pten causes premature activation of the primordial follicle pool. Science 319, 611-613 (2008). (Pubitemid 351197061)
21. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006). (Pubitemid 44050144)
22. Stambolic, V. et al. Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325 (2001). (Pubitemid 32831549)
23. Wang, X. & Jiang, X. Post-translational regulation of PTEN. Oncogene 27, 5454-5463 (2008).
24. Wang, X. et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128, 129-139 (2007). (Pubitemid 46048884)
25. Fouladkou, F. et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc. Natl. Acad. Sci. USA 105, 8585-8590 (2008). (Pubitemid 351987724)
26. Chen, A. et al. The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. Mol. Cellular Biol. 29, 5348-5356 (2009).
27. Li, H. et al. WWP2-mediated ubiquitination of the RNA polymerase II large subunit in mouse embryonic pluripotent stem cells. Mol. Cellular Biol. 27, 5296-5305 (2007). (Pubitemid 47124385)
28. McDonald, F. J. et al. Ubiquitin-protein ligase WWP2 binds to and downregulates the epithelial Na(+) channel. Am. J. Physiol. Renal Physiol. 283, F431-F436 (2002).
29. Xu, H. M. et al. WWP2, an E3 ubiquitin ligase that targets transcription factor Oct-4 for ubiquitination. J. Biol. Chem. 279, 23495-23503 (2004). (Pubitemid 38685661)
30. Yim, E. K. et al. Rak functions as a tumour suppressor by regulating PTEN protein stability and function. Cancer Cell 15, 304-314 (2009).
31. Georgescu, M. M. et al. Stabilization and productive positioning roles of the C2 domain of PTEN tumour suppressor. Cancer Res. 60, 7033-7038 (2000).
32. Andres-Pons, A. et al. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumour suppressor PTEN. Cancer Res. 67, 9731-9739 (2007). (Pubitemid 47621220)
33. He, X., Ni, Y., Wang, Y., Romigh, T. & Eng, C. Naturally occurring germline and tumour-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Human Mol. Genet. 20, 80-89 (2011).
34. Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumour suppression. Cell 128, 141-156 (2007). (Pubitemid 46048885)
35. Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K. & Donner, D. B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277, 5484-5489 (2002). (Pubitemid 34968598)
36. Zhou, M., Gu, L., Findley, H. W., Jiang, R. & Woods, W. G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 63, 6357-6362 (2003). (Pubitemid 37255184)
37. Kato, H. et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res. 6, 3937-3943 (2000).
38. Jin, G. et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69, 279-283 (2010).
39. Bernassola, F., Karin, M., Ciechanover, A. & Melino, G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14, 10-21 (2008). (Pubitemid 351885498)
40. Maddika, S. & Chen, J. Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. Nat. Cell Biol. 11, 409-419 (2009).